SESteven V. Edelman

Steven V. Edelman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven V. Edelman has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Pharmacy Benefit Manager Organizations on Diabetes Management

    by Irl B. Hirsch, Christopher G. Parkin, Kenneth Moritsugu, Grazia Aleppo, George Grunberger, Janet B. McGill, Viral N. Shah, Carol J. Levy, Marissa Bowdler, Bruce Taylor, et al.

    Pharmacy benefit managers (PBMs) administer prescription drug benefits for insurers, employers, and other payers through formulary design, rebate negotiation, pharmacy network management, and utilization controls. In diabetes care, cost-containment strategies such as formulary-driven medication switching, step therapy, and formulary exclusivity have increasingly restricted access to essential medications and technologies. These rebate-driven practices often prioritize financial incentives over clinical appropriateness, leading to forced nonmedical switching, higher out-of-pocket costs, reduced adherence, and poorer glycemic outcomes. This narrative review examines how PBM-driven policies undermine patient-centered, evidence-based diabetes care and disrupt continuity of treatment. Greater transparency, preservation of patient and clinician choice, and policies that align PBM incentives with clinical outcomes are needed to reduce harm and improve access to appropriate diabetes therapies.

  • Open Access

    Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report

    by Guillermo E. Umpierrez, Viral N. Shah, Veronica Brady, Mark A. Clements, Juan Espinoza, Elizabeth Healey, Michael A. Kohn, David M. Maahs, Ralph Oiknine, Jane J. Seley, et al.

    A panel of experts in the use of continuous glucose monitoring (CGM) data in the treatment of diabetes met in Burlingame, California on October 27, 2025 to discuss the utility of the glycemia risk index (GRI) for clinical care research and population health management. The GRI composite metric is a single number (on a 0-100 percentile scale—lower is better) based on an expert-determined weighting of the seven individual components in the existing ambulatory glucose profile (AGP). The GRI describes the quality of glycemia based on glucose values collected in a 14-day CGM tracing, thus providing additional insights into CGM profiles beyond the AGP. During the meeting, the mathematical derivation of the GRI metric was presented along with its use for adult and pediatric individuals with diabetes and cancer who require medications that can adversely affect the glucose concentration. Examples where the GRI provided useful insights into the quality of CGM tracings were also discussed by the expert panel. In addition, a new smartphone application, the GRI Calculator, was presented. This app calculates the GRI of a CGM tracing and provides visualization of sequential CGM tracings for a specific individual. The GRI provides a reference measurement for the accuracy of artificial intelligence (AI) models assigning levels of glycemic quality to CGM tracings intended to match the assessments of clinicians. The GRI is now part of the data visualization panel for the Integration of Connected Diabetes Device Data into the Electronic Health Record (iCoDE-2) project, which standardizes both CGM and insulin dosing data. Further exploration of the potential value of the GRI for non-insulin users needs to be undertaken. The panel unanimously recommended that CGM manufacturers and developers of data visualization software for CGMs add the GRI to their data platforms for insulin users.


  • Open Access

    Risk of new‐onset type 1 diabetes in individuals with celiac disease and thyroid disease—An observational study

    by Steve V. Edelman, Daniel Agardh, Nancy Cui, Lichen Hao, Mattias Wieloch, Luigi Meneghini

    Aims: The objective of this study was to compare the risk of developing type 1 diabetes in individuals with celiac disease, hyperthyroidism and hypothyroidism to that of individuals without those conditions. Materials and Methods: In this retrospective, observational, matched‐cohort study based on real‐world claims data, individuals with at least one diagnosis of celiac disease, hyperthyroidism (e.g. Graves' disease) or hypothyroidism (e.g. Hashimoto's disease) and a control cohort of individuals without any of these three conditions were included. Individuals from the disease and control cohorts were propensity score matched 1:1 based on baseline demographics and clinical characteristics. A Cox proportional hazards model was used to compare the risk of type 1 diabetes between cohorts. Results: Type 1 diabetes developed in 0.14% (68/47 099) of individuals with celiac disease compared to 0.06% (27/47 099) of controls. Of those with hyperthyroidism, type 1 diabetes developed in 0.17% (281/164 830) compared to 0.06% (99/164 830) of controls. Of those with hypothyroidism, type 1 diabetes developed in 0.18% (1756/980 477) compared to 0.08% (764/980 477) of controls. The risk of developing type 1 diabetes was increased for each of the disease cohorts compared to their respective controls (celiac disease: HR = 2.54 [ p < 0.0001]; hyperthyroidism: adjusted HR = 2.98 [ p < 0.0001]; hypothyroidism: HR = 2.41 [ p < 0.0001]); risk was highest among individuals aged <18 years. Conclusions: The risk of developing type 1 diabetes was significantly higher for individuals with celiac disease or thyroid disease compared to those without any of these conditions. These findings support the screening of individuals with these conditions for stage 2 type 1 diabetes.


  • Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Health Care Costs: A Comparative Analysis by Insurance Type

    by Jason C. Allaire, Consuela Dennis, Eugene E. Wright, Steven V. Edelman, Arti Masturzo

    This real-world analysis compared adherence rates, total health care costs, and health care resource utilization of individuals receiving continuous glucose monitoring (CGM) supplies through durable medical equipment (DME) providers versus through pharmacies, according to insurance type. Patients in the DME cohort had higher adherence rates than those in the pharmacy cohort. Total costs were lower for Medicare/Medicare Advantage patients getting supplies from a DME than for patients getting supplies from a pharmacy. Among those with commercial insurance, health care utilization was lower in the DME cohort than in the pharmacy cohort. Sourcing CGM supplies from DME providers versus pharmacies may yield benefits on adherence, health care costs, and resource utilization.


  • Open Access

    Improved glycemic outcomes in people with type 2 diabetes using smart blood glucose monitoring integrated with popular digital health therapeutics

    by Mike Grady, Elizabeth Holt, Hilary Cameron, Steven Edelman

    The increasing prevalence of metabolic syndrome and type 2 diabetes places a burden on healthcare systems, necessitating cost-effective, engaging and accessible interventions to address the underlying behavioral and lifestyle drivers. Our study evaluated combining Bluetooth connected OneTouch blood glucose meters (BGM) and the OneTouch Reveal mobile app with one of four digital therapeutic apps. Each group was independent, with people with type 2 diabetes (PwT2D) themselves choosing their therapeutic intervention, to better reflect real-world use. Our 3-month decentralized study screened 912 subjects, with 612 returning mail-in A1cs, providing 191 subjects (Noom = 68, Fitbit = 31, Cecelia Health = 47, Welldoc = 45) who met all inclusion criteria, including entry A1c 7.5 to 12.0%. The primary endpoint of A1c change showed improvement in the overall group by − 0.77% (95% CI − 0.98 to − 0.56, n = 141) after 3-months, Noom − 1.03% (CI − 1.4 to − 0.61, n = 49), Fitbit − 0.56% (CI − 1.0 to − 0.11, n = 24), Cecelia Health − 0.76% (CI − 1.2 to − 0.36, n = 36), Welldoc − 0.55% (CI − 0.94 to − 0.17, n = 32). In terms of secondary endpoints, more than half (56%) of these PwT2D lowered A1c by ≥ 0.5% and more than a third (36%) lowered A1c by ≥ 1.0%, with similar improvements across each of the four independent groups. Our real-world approach shows the potential for connected BGMs and widely accessible digital therapeutics to contribute to improvements in glycemic outcomes.


  • Expert Clinical Interpretation of Continuous Glucose Monitor Reports From Individuals Without Diabetes

    by Nicole L. Spartano, Brenton Prescott, Maura E. Walker, Eleanor Shi, Guhan Venkatesan, David Fei, Honghuang Lin, Joanne M. Murabito, David Ahn, Tadej Battelino, et al.

    Background: Clinical interpretation of continuous glucose monitoring (CGM) data for people without diabetes has not been well established. This study aimed to investigate concordance among CGM experts in recommending clinical follow-up for individuals without diabetes, based upon their independent review of CGM data. Methods: We sent a survey out to expert clinicians ( n = 18) and asked them to evaluate 20 potentially challenging Dexcom G6 Pro CGM reports (and hemoglobin A1c [HbA1c] and fasting venous blood glucose levels) from individuals without diabetes. Clinicians reported whether they would recommend follow-up and the reasoning for their decision. We performed Fleiss Kappa interrater reliability to determine agreement among clinicians. Results: More than half of expert clinicians (56-100%, but no clear consensus) recommended follow-up to individuals who spent >2% time above range (>180 mg/dL), even if HbA1c <5.7% and fasting glucose <100 mg/dL. There were no observed trends for recommending follow-up based on mean glucose or glucose management indicator. Overall, we observed poor agreement in recommendations for who should receive follow-up based on their CGM report (Fleiss Kappa = 0.36). Conclusions: High discordance among expert clinicians when interpreting potentially challenging CGM reports for people without diabetes highlights the need for more research in developing normative data for people without diabetes. Future work is required to develop CGM criteria for identifying potentially high-risk individuals who may progress to prediabetes or type 2 diabetes.


  • Open Access

    Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative Review

    by Diana Brixner, Steven V. Edelman, Ray Sieradzan, James R. Gavin

    The growing prevalence of type 2 diabetes (T2D) remains a leading health concern in the US. Despite new medications and technologies, glycemic control in this population remains suboptimal, which increases the risk of poor outcomes, increased healthcare resource utilization, and associated costs. This article reviews the clinical and economic impacts of suboptimal glycemic control in patients on basal-bolus insulin or multiple daily injections (MDI) and discusses how new technologies, such as tubeless insulin delivery devices, referred to as “patch pumps”, have the potential to improve outcomes in patients with T2D.


  • Open Access

    Patient Perspectives on the Benefits and Challenges of Diabetes and Digital Technology

    by Steve Edelman, Wayman W. Cheatham, Anna Norton, Kelly L. Close

    Diabetes technology continues to evolve, advancing with our understanding of human biology and improving our ability to treat people with diabetes. Diabetes devices are broadly classified into the following categories: glucose sensors, insulin delivery devices, and digital health care technology (i.e., software and mobile applications). When supported by education and individually tailored, technology can play a key role in optimizing outcomes. Digital devices assist in diabetes management by tracking meals, exercise, sleep, and glycemic measurements in real time, all of which can guide physicians and other clinicians in their decision-making. Here, as people with diabetes and patient advocates, as well as diabetes specialists, primary care providers, and diabetes care and education specialists, we present our perspectives on the advances, benefits, and challenges of diabetes technology in primary care practices.


  • Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)

    by Steven Edelman, Jennifer Goldman, Daniel C. Malone, Ronald Preblick, Kovida Munaga, Xuan Li, Jasvinder Gill, Sumana Gangi

    People with type 2 diabetes receiving a second-generation basal insulin (BI) analog may be switched to a first-generation formulation for financial reasons or changes in health insurance. However, because second-generation BI analogs have more even pharmacokinetic profiles, longer durations of action (>24 vs. ≤24 hours), and more stable action profiles than first-generation BI analogs, such a change may result in suboptimal treatment persistence and/or adherence. This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI. The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI.


  • Open Access

    Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist

    by Steven Edelman, Doreen Cassarino, David Kayne, Terry Dex, Xuan Li, Francisco J Pasquel

    BACKGROUND: Fixed-ratio combinations of basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have greater simplicity of administration with expected improved adherence/persi...